Man Group’s DiaMedica Therapeutics DMAC Stock Holding History

Man Group’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,414	Closed	-$133K	–	2306
2025 Q3	$133K	Buy	+19,414	New	+$105K	﹤0.01%	2139

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Man Group's DMAC Position: Q4 2025 in Review

Man Group sold out of DiaMedica Therapeutics (DMAC) in Q4 2025, closing a stake of 19,414 shares — an estimated $133K sold.

Man Group first reported a position in DMAC in Q3 2025 and held it in 1 quarter. The position peaked at $133K in Q3 2025. 92 funds tracked by Wall St. Rank hold DMAC as of Q4 2025.

Man Group reported no remaining DiaMedica Therapeutics position as of Q4 2025 after selling out during the quarter.
Man Group sold 19,414 DiaMedica Therapeutics shares in Q4 2025, an estimated $133K.
Man Group first reported a position in DiaMedica Therapeutics in Q3 2025 and held it in 1 quarter.
Man Group's DiaMedica Therapeutics position peaked at $133K in Q3 2025.
92 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2025.

Based on Man Group's 13F filing for Q4 2025, filed 17 Feb 2026.